AstraZeneca’s Brilinta gets FDA priority review for potential new indication
Brilinta is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs) and it works by inhibiting platelet activation. The sNDA is